FindTrial
Sign In

Percutaneous intraductal radiofrequency ablation with metal stenting versus metal stenting alone for treating malignant biliary obstruction

Percutaneous intraductal radiofrequency ablation with metal stenting versus metal stenting alone for treating malignant biliary obstruction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16008022
Enrollment
Unknown
Registered
2016-02-29
Start date
2016-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant biliary obstruction

Interventions

A:percutaneous intraductal radiofrequency ablation with metal stenting
B:metal stenting alone

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. biliary tumors with obstructive jaundice; 2. The feasible PTCD yellow reduction treatment; 3. The male and female subjects, year full 18 one full year of life; 4. The life expectancy of at least 1 month; 5. The patient or family signed consent to treatment.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2.Any contraindications for hepatic embolization procedures(known renal failure/insufficiency requiring hemo-or peritoneal dialysis); 3. Patients with prior malignancy were ineligible for the study, with the exception of those who had been disease free for longer than 5 years; 4. Patients with liver transplantation

Design outcomes

Primary

MeasureTime frame
Overall Survival;—

Secondary

MeasureTime frame
Stent Patency Time;—

Countries

China

Contacts

Public ContactLi Jiaping
jpli3s@126.com+86 13352890908

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026